口服降糖药钠葡萄糖协同转运蛋白2抑制剂的研究进展
作者：吕秋菊;钟怡;张晋;刘欢;许丹;
Author：
收稿日期： 年卷（期）页码：2017,32(03):-326-329
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：糖尿病;钠葡萄糖协同转运蛋白2抑制剂;达格列净;卡格列净;伊格列净;依帕列净;空腹血糖;糖化血红蛋白
Key words：
基金项目：
中文摘要
新型口服降糖药钠葡萄糖协同转运蛋白2(SGLT2)抑制剂达格列净、卡格列净、伊格列净、依帕列净等发挥降血糖作用主要依赖抑制肾小管重吸收葡萄糖,不依赖于胰岛素的作用。临床试验发现:SGLT2抑制剂无论单用还是与传统降糖药合用,都能明显降低2型糖尿病患者的空腹血糖,糖化血红蛋白(HbA_(1C)),兼具降低体重和血压的作用。不良反应方面,SGLT2抑制剂并不会增加低血糖、乳腺癌、膀胱癌和心血管事件等风险,但尿路感染、生殖器感染与低血压的发生率可能增加。
参考文献
[1]Yang W,Lu J,Weng J,et al.Prevalence of diabetes among men and women in China[J].New Eng J Med,2010,362(12):1090-1101.
[2]Wright EM,Hirayama B,Loo D.Active sugar transport in health and disease[J].J Internal Med,2007,261(1):32-43.
[3]Wright EM,Loo DD,Hirayama BA.Biology of human sodium glucose transporters[J].Physiol Rev,2011,91(2):733-794.
[4]Bailey CJ,Morales VEC,Woo V,et al.Efficacy and safety of Dapagliflozin monotherapy in people with Type 2 diabetes:A randomized double-blind placebo-controlled 102-week trial[J].Diabet Med,2015,32(4):531-541.
[5]Wilding J,Woo V,Soler N,et al.Long-term efficacy of Dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin[J].Deut Med Wochenschr,2013,138:S27-39.
[6]Jabbour SA,Hardy E,Sugg J,et al.Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin:A 24-week,multicenter,randomized,double-blind,placebocontrolled study[J].Diabetes Care,2014,37(3):740-750.
[7]Nauck MA,Del Prato S,Duran-Garcia S,et al.Durability of glycaemic efficacy over 2 years with Dapagliflozin versus Glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin[J].Diabetes Obes Metab,2014,16(11):1111-1120.
[8]Bailey CJ,Gross JL,Hennicken D,et al.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin:A randomized,double-blind,placebo-controlled102-week trial[J].BMC Med,2013,11:193.
[9]Rosenstock J,Hansen L,Zee P,et al.Dual add-on therapy in type 2 diabetes poorly controlled with Metformin monotherapy:A randomized double-blind trial of Saxagliptin plus Dapagliflozin addition versus single addition of Saxagliptin or Dapagliflozin to metformin[J].Diabetes Care,2015,38(3):376-383.
[10]Kohan DE,Fioretto P,Tang W,et al.Long-term study of patients with type 2 diabetes and moderate renal impairment shows that Dapagliflozin reduces weight and blood pressure but does not improve glycemic control[J].Kidney Int,2014,85(4):962-971.
[11]Leiter LA,Cefalu WT,de Bruin TW,et al.Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease:A 24-week,multicenter,randomized,double-blind,placebo-controlled study with a 28-week extension[J].J Am Geriatr Soc,2014,62(7):1252-1262.
[12]Henry RR,Rosenstock J,Edelman S,et al.Exploring the potential of the SGLT2 inhibitor Dapagliflozin in type 1 diabetes:A randomized,double-blind,placebo-controlled pilot study[J].Diabetes Care,2015,38(3):412-419.
[13]Stenlof K,Cefalu WT,Kim KA,et al.Long-term efficacy and safety of Canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise:Findings from the 52-week CANTATA-M study[J].Curr Med Res Opin,2014,30(2):163-175.
[14]Forst T,Guthrie R,Goldenberg R,et al.Efficacy and safety of Canagliflozin over 52 weeks in patients with type 2 diabetes on background Metformin and Pioglitazone[J].Diabetes Obes Metab,2014,16(5):467-477.
[15]Ji L,Han P,Liu Y,et al.Canagliflozin in Asian patients with type2 diabetes on Metformin alone or Metformin in combination with sulphonylurea[J].Diabetes Obes Metab,2015,17(1):23-31.
[16]Bode B,Stenlof K,Sullivan D,et al.Efficacy and safety of Canagliflozin treatment in older subjects with type 2 diabetes mellitus:A randomized trial[J].Hosp Pract(1995),2013,41(2):72-84.
[17]Leiter LA,Yoon KH,Arias P,et al.Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus Glimepiride in patients with type 2 diabetes on Metformin:A randomized,double-blind,phase 3 study[J].Diabetes Care,2015,38(3):355-364.
[18]Neal B,Perkovic V,de Zeeuw D,et al.Efficacy and safety of Canagliflozin,an inhibitor of sodium glucose cotransporter 2,when used in conjunction with insulin therapy in patients with type 2diabetes[J].Diabetes Care,2015,38(3):403-411.
[19]Yamout H,Perkovic V,Davies M,et al.Efficacy and safety of Canagliflozin in patients with type 2 diabetes and stage 3nephropathy[J].Am J Nephrol,2014,40(1):64-74.
[20]Kashiwagi A,Kazuta K,Yoshida S,et al.Randomized,placebocontrolled,double-blind glycemic control trial of novel sodiumdependent glucose cotransporter 2 inhibitor Ipragliflozin in Japanese patients with type 2 diabetes mellitus[J].J Diabetes Investig,2014,5(4):382-391.
[21]Wilding J,Ferrannini E,Fonseca V,et al.Efficacy and safety of Ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin:A dose-finding study[J].Diabetes Obe Metab,2013,15(5):403-409.
[22]Kashiwagi A,Kazuta K,Goto K,et al.Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2diabetes:ILLUMINATE,a randomized,double-blind,placebocontrolled study[J].Diabetes Obes Metab,2015,17(3):304-308.
[23]Kashiwagi A,Takahashi H,Ishikawa H,et al.A randomized,double blind,placebo-controlled study on long-term efficacy and safety of Ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment:Results of the LANTERN study(Long-term ASP1941 safety evaluation in T2DM patients with renal impairment)[J].Diabetes Obes Metab,2015,17(2):152-160.
[24]Kadowaki T,Haneda M,Inagaki N,et al.Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus:A randomized,12-week,double-blind,placebo-controlled,phaseⅡtrial[J].Adv Ther,2014,31(6):621-638.
[25]Rosenstock J,Seman L,Jelaska A,et al.Efficacy and safety of Empagliflozin,a sodium glucose cotransporter 2(SGLT2)inhibitor,as add-on to Metformin in type 2 diabetes with mild hyperglycaemia[J].Diabetes Obes Metab,2013,15(12):1154-1160.
[26]Ridderstrale M,Andersen KR,Zeller C,et al.Comparison of Empagliflozin and Glimepiride as add-on to Metformin in patients with type 2 diabetes:A 104-week randomised,activecontrolled,double-blind,phase 3 trial[J].Lancet Diabetes Endo,2014,2(9):691-700.
[27]Kovacs C,Seshiah V,Swallow R,et al.Empagliflozin improves glycaemic and weight control as add-on therapy to Pioglitazone or Pioglitazone plus Metformin in patients with type 2 diabetes:A24-week,randomized,placebo-controlled trial[J].Diabetes Obes Metab,2014,16(2):147-158.
[28]Haring HU,Merker L,Seewaldt-Becker E,et al.Empagliflozin as add-on to Metformin in patients with type 2 diabetes:A 24-week,randomized,double-blind,placebo-controlled trial[J].Diabetes Care,2014,37(6):1650-1659.
[29]Barnett AH,Mithal A,Manassie J,et al.Efficacy and safety of Empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease:A randomised,double-blind,placebo-controlled trial[J].Lancet Diabetes Endo,2014,2(5):369-384.
[30]Seino Y,Sasaki T,Fukatsu A,et al.Efficacy and safety of Luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus:A randomized,double-blind,placebo-controlled,phase 3 study[J].Curr Med Res Opin,2014,30(7):1245-1255.
[31]Kaku K,Watada H,Iwamoto Y,et al.Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor Tofogliflozin in Japanese patients with type 2 diabetes mellitus:A combined Phase 2 and 3 randomized,placebo-controlled,double-blind,parallel-group comparative study[J].Cardiovasc Diabetol,2014,13(1):65.
[32]Rosenstock J,Cefalu WT,Lapuerta P,et al.Greater doseranging effects on A1C levels than on glucosuria with LX4211,a dual inhibitor of sodium glucose transporters SGLT1 and SGLT2,in type 2 diabetes on Metformin monotherapy[J].Diabetes Care,2015,38(3):431-438.
[33]Vasilakou D,Karagiannis T,Athanasiadou E,et al.Sodiumglucose cotransporter 2 inhibitors for type 2 diabetes:A systematic review and meta-analysis[J].Ann Intern Med,2013,159(4):262-274.
【关闭】
